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Resistance to facuhative intracellular pathogens is mediated through the activities 
of immunologically committed lymphocytes and the bactericidal activities of macro- 
phages  (1-3).  Mononuclear  phagocytes  from  infected animals  show  characteristic 
changes in  "marker" enzymes (4), exhibit increased phagocytic activity (1,  3), and 
spread more rapidly and more extensively in vitro than macrophages from normal 
animals (5-7). The spreading of mononuclear phagocytes in vitro has been correlated 
kinetically  with  increased  bactericidal  activity  in  vivo  (8);  for  this  reason,  the 
macrophage spreading reaction has been viewed as one in vitro manifestation of a 
state of increased macrophage activity in vivo. A  wide variety of agents have been 
reported to induce macrophage spreading in  vitro. These include proteases,  metal 
ions, and cationic anesthetics (7). Recently it has been shown that activated factor B 
(Bb),l the central serine esterase of the alternative pathway of complement activation 
(APC)  (9), induces murine macrophages (10)  and human monocytes (11)  to spread. 
Expression of monocyte spreading activity by Bb requires that  the catalytic site be 
structurally  intact  because  treatment  with  heat  (56°C  for 30  min)  or  diisopropyl 
fluorophosphate (10  -a M) destroys both enzymatic and spreading activities (9-11). 
Native factor B (B) is a protein of 93,000 mol wt that enters into a Mg÷+-dependent 
complex with C3b (12) and is cleaved by factor D  (13), yielding fragments of 60,000 
and 33,000 mol wt, termed Bb and Ba, respectively (9, 12,  14). The C3b,Bb complex 
serves as the convertase of the APC, which cleaves C3 and C5 (9,  12,  14). Enzymatic 
activity of the  C3b,Bb  complex resides  in  the  Bb  fragment, which  retains  limited 
esterolytic activity after it is released from the complex by decay dissociation (9,  13, 
15). Considering  the  restricted  substrate  specificity of C3b,Bb  in  the  complement 
system, the question arose as to whether either of the natural substrates of Bb, namely 
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C3  or C5,  might  serve  as  a  monocyte-surface  substrate  of Bb.  Activation  of C5  by 
C3b,Bb  is  the  central  event  initiating  assembly  by  the  APC  of  the  C5b,6,7,8,9 
(C5b-9)  membrane attack complex in serum  (16). 
Materials  and Methods 
Media.  Medium  199 and RPMI  1640 were purchased  from Grand Island Biological Co., 
Grand Island, N.Y. After supplementing these media with glutamine (100 #g/ml), nonessential 
amino acids, pyruvate (1  mM)  and penicillin,  streptomycin, and fungizone,  the media were 
mixed 1:1 for use in monocyte cultures (17). 
Complement Proteins and Antiserum to Complement.  Complement proteins Clq (18), C3 (19), C4 
(20),  C5  (21),  and  factor B  (12),  were prepared as described  previously. The b  fragment of 
factor B (Bb) was prepared as described previously (9, 10, 12) by cleaving factor B with factor 
D in the presence of C3b (22). Bb was separated from the other reactants by chromatography 
at low ionic strength on DE-32 (Whatman, Inc., Clifton, N. J.)  (12). 
Antisera  was  raised  in  goats  to  Clq,  C3,  C4,  C5.  The  specificity of these  antisera  was 
established by two-directional radial immunodiffusion and immunoelectrophoresis in agarose 
using normal human serum (NHS), purified serum proteins, and purified complement proteins 
as  antigens.  In  certain  experiments,  described  in  the  text,  the  specificity of anti-C5  Fab' 
antibody  fragments was verified by absorbing with C5, which was purified by conventional 
procedures (21) and then subjected to additional purification by electrophoresis on and elution 
from alkaline 7.5% polyacrylamide gels (23). 
Antibody Fragments Directed toward Complement Proteins.  An immunoglobulin (Ig) fraction was 
prepared from goat antiserum by precipitating Ig at 33% ammonium sulfate saturation twice. 
F(ab')z fragments of antibody were prepared by digesting Ig with 4% (wt:wt)  pepsin (Sigma 
Chemical Co., St. Louis, Mo.) for 16-36 h at 37°C, pH 3.8, in 0.12 M  acetate-buffered 0.15 M 
saline (ABS).  F(ab')z was separated from nondigested Ig by molecular-sieve chromatography 
on Ultrogel Aca 34 (LKB Instruments, Rockville, Md.) in 0.1 M glycine-NaOH buffer, pH 8.0, 
containing 0.15 M sodium chloride (GBS), and Fab' fragments of goat antibody were prepared 
by reducing F(ab')a fragments for 60 min at 37°C with 0.04 M cysteine in GBS, alkylating with 
0.025  M  iodacetamide for 60 min at 37°C, and separating Fab' from nonreduced  F(ab')2 by 
molecular-sieve chromatography on Uhrogel Aca 44 (LKB Instruments).  Fab were prepared 
by digesting goat Ig with 1% papain (wt:wt) (activated in 0.01 M cysteine and 0.002 M  EDTA) 
for 18 h at 37°C in 0.15 M  phosphate buffer, pH 7.0. Fab was separated from nondigested Ig 
and Fc by molecular-sieve chromatography on Ultrogel Aca 44 in GBS. 
Antibody fragments were prepared for use in studies with human monocytes by dialyzing for 
16 h against phosphate-buffered (0.01 M) saline (0.14 M), (PBS), pH 7.2, and for 16 h against 
tissue  culture  medium.  The molecular size homogeneity of goat  Ig, F(ab')2, Fab', and  Fab 
fragments used in these experiments was verified by sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) according to the method of Weber and Osborn (24). 
Monocytes.  To prevent  complement  activation,  human  blood  was collected  directly into 
EDTA  (final concentration  of 20 mM EDTA)  and monocytes were prepared by a  four-step 
procedure described previously (11). Briefly, leukocytes were separated by sedimentation, first, 
on density 1.09 g/ml Ficoll-Hypaque; second, on density 1.077 g/ml Ficoll-Hypaque; third, at 
low speed to remove platelets; and, fourth, on linear 2.7-5.5% Ficoll gradients. These procedures 
yielded a cell preparation that was composed of >90% monocytes and <10% lymphocytes by 
several  criteria  (11).  Monocytes  were  separated  from  iymphocytes  by  adherence  to  glass 
coverslips (13-mm Diam; Clay Adams, Parsippany, N. J.)  in microtiter wells (16-mm Diam; 
Falcon Labware, Oxnard, Calif.), for 16 h at 37°C in medium containing 20% heat-inactivated 
(54°C for 60 min) autologous serum. Nonadherent lymphocytes were removed by washing with 
medium,  serum-containing  medium  was  replaced  with  serum-free  medium,  and  adherent 
monocytes (-2-4 ×  10S/coverslip) were incubated for 3 d in serum-free medium to effect their 
maturation to macrophages and to increase their responsiveness to factor Bb (11). Monocytes 
used for spreading assays were >95% monocytes by morphology after Wright staining, >80% 
phagocytized carbonyl iron latex particles, >75 and >85% possessed receptors for Fc or C3b, 
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Detection of C3 and C5 on Monoeytes by the Direct Immunofluorescent Antibody Technique.  Anti-C3 
F(ab')2 and anti-C5 F(ab')2 were conjugated with fluorescein isothioeyanate (FITC) for use in 
immunofluorescence microscopic studies  as  described previously  (25).  Immunofluorescence 
staining of cells was accomplished by treating adherent  monocytes on  glass cove/slips with 
fluorescent antibody fragments at a concentration of 0.6 mg/ml protein in medium for 30 rain 
at 37°C. Cultures were then washed three times with medium, and examined as a wet mount 
preparation using a Zeiss photoscope III (Carl Zeiss, Inc., New York) equipped for epifluorescent 
illumination with a  BG 450-490  excitation filter, FT510  beam splitter, and  BP  520 barrier 
filter. 
Assay for Factor Bb-induced Monocyte Spreading.  Spreading of human monocytes was assayed as 
described previously (11)  by adding 0.3  ml of 3/zg factor Bb/ml  to  3-d human  monocyte 
cultures on glass cove/slips. Monocytes treated with factor Bb for 3 h were spread two to three 
times  wider  and  up  to  six  to  eight  times  longer  than  control  untreated  monocytes  (11). 
Measurements of cell surface area and circumference were performed using planimetry and 
phase-contrast photomicrographs of monocytes at a  final magnification of ×  2,500.  Adherent 
human  monocytes were  found  to  have  a  cell-surface area of 400  ±  100  m#  a  (SD)  and  a 
circumference of 56 ±  10 rn# (SD); in contrast, monocytes treated with factor Bb for 3 h were 
found to have a cell surface area of 2,100 +  400 m/z  2 (SD) and a circumference of 230 ±  80 m# 
(SD). For routine analysis, spreading was assessed microscopically on viable cultures at ×  400 
magnification using an inverted microscope fitted with a 0.5-mm ocular grid. A monocyte was 
considered to be spread if at least one of its dimensions was more than twice that of "unspread" 
monocytes in control cultures. The percentage of spread monocytes was determined by counting 
two to three microscopic fields (containing 200-300 cells) for each cove/slip culture. The mean 
percentage ±  standard  deviation was  calculated from  the  results of duplicate or triplicate 
samples. 
Assays for Inhibition of Monocyte Spreading.  Inhibition of monocyte spreading by Fab' or Fab 
antibody fragments was assayed by adding 0.3 ml of dilutions of Fab' or Fab in medium to 3- 
d  cultures of glass-adherent monocytes for  15  min  at  37°C.  The  responsiveness of treated 
monocytes was tested by adding I0 #l of a stock solution of 90 #g factor Bb/ml, and by counting 
the number of spread and unspread cells after 3 h, as described above. 
Radiolabeling of C5 in Monoeyte Extracts with [t4C]- and [3HJLag.ine.  Biosynthesis of C5 by 
monocytes was investigated by preparing monocytes from 1-2 liters of fresh human blood by 
a modification of the four-step procedure described above. Briefly, monocytes were prepared by 
centrifugation (2,000  rpm for 20 rain) on 80 ml of Ficoll-Hypaque 1.09 g/ml and then  1.077 
g/ml  in  250-ml  centrifuge  bottles  using  an  International  PR-2  centrifuge  (International 
Equipment C,o., Needham Heights, Mass.). The remaining preparative steps were performed as 
described previously (11).  Conditions for radiolabeling with [SH]- or [14C]leucine  (120 or 325 
mCi/mM, respectively; New England Nuclear, Boston, Mass.) are described in the text. After 
labeling, adherent monocytes were washed three times with medium and twice with PBS, and 
then extracted with 100-200 ml of 1% Triton X-100 in 2 mM sodium carbonate buffer, pH 7.5, 
containing  1.0 mM phenylmethylsulfonylflouride. Extracts were centrifuged  12,000 g  for 30 
rain to remove cellular debris, and concentrated by uhrafihration on Amicon PM30 membranes 
(Amicon Corp., Lexington, Mass.)  to a  final volume of I-2 ml. Samples were analyzed for 
radiolabeled C5 by adding goat anti-C5 Ig and  10% NHS (as a carrier antigen); immunopre- 
cipitates were collected by centrifugation, washed, and dissociated in ABS, pH 3.0, containing 
I% SDS; solubilized precipitates were analyzed by SDS-PAGE (24).  Radioactivity was deter- 
mined by slicing the acrylamide gels, solubilizing them in Protosol (New England Nuclear), 
and by counting in a Beckman LS 230 liquid scintillation counter (Beckman Instruments, Inc., 
Fullerton, Calif.). In other experiments, moncytes were labeled with [i*C]leucine and C5 was 
precipitated with goat anti-C5 Ig by double immunodiffusion in 2%  agarose containing 1% 
Triton X-100. Nonspeeifically trapped radioactivity was removed by washing twice a day for 
5 d with veronal-buffered saline containing 1% Triton; then for 1 d with PBS; and finally for 
1 d with distilled water. Specifically bound radioactivity was determined by autoradiography 
for 20 d with X-ray film (Eastman Kodak Co., Rochester, N. Y.). 766  COMPLEMENT-DEPENDENT  MONOCYTE  SPREADING 
Results 
Experiments were performed to investigate whether C3 or C5 were expressed on 
the monocyte surface, and whether these proteins play a role in the spreading reaction 
induced by Bb. 
Demonstration of C3  and  C5 Antigens on  Monocytes by  the  Direct Fluorescent Antibody 
Technique.  The expression of C3 and C5 on monocytes was investigated by the direct 
immunofluorescent  antibody  technique  employing monospecific  FITC-conjugated 
goat anti-C3 and anti-C5 F(ab')2 antibody fragments. Positive immunofluorescence 
staining was observed with FITC-conjugated anti-C5  F(ab')2 on 6  +  7% of freshly 
prepared monocytes and on 70 +  6% of monocytes incubated for 3 d in vitro in serum- 
free medium. The fluorescence micrographs presented in Fig.  1 show patching and 
capping of cell-surface determinants, which were stained by anti-C5 F(ab')2 at 37°C. 
In parallel studies, the expression of C3 on monocytes was investigated and weak 
fluorescence staining was observed with FITC-conjugated anti-C3 F(ab')2 on 6 +  5% 
of freshly prepared monocytes. The percentage of cells  stained positively for C3 did 
not increase significantly during in vitro incubation. 
Detection of Radiolabeled C5 in Extracts of Monocytes Incubated with  [14C]- and [aH]- 
Leucine.  Experiments were conducted to investigate whether monocytes biosynthet- 
ically incorporate [3H]leucine into C5 during 7 d of in vitro incubation in serum-free 
medium. The results presented in Fig. 2 indicate that anti-C5 Ig precipitates a tritium- 
labeled monocyte protein that has the same mobility in SDS-PAGE as purified C5 
run in a replicate gel. In other experiments, the kinetics of C5 synthesis was investi- 
gated by incubating monocytes with [14C]leucine, extracting cells with Triton X-100, 
Fie.  1.  Positive immunofluorescence staining at  37°C of human peripheral  blood monocytes by 
FITC-conjugated goat anti-C5 F(ab')2: monocyte cultures maintained for 3 d  in vitro in serum-free 
medium before staining; original magnification X 660. JOHN S.  SUNDSMO AND OTTO GOTZE  767 
FIG. 2.  Incorporation of [nH]leucine by human peripheral blood monocytes  into immunoprecip- 
itable C5-antigen, which was extracted from  cells with Triton X-100 and detected on SDS-PAGE 
by scintillation counting of gel slices: the upper panel is purified C5; the lower panel is immuno- 
precipitable monoeyte  C5 run on a replicate gel. 
and  precipitating  radiolabeled  C5  antigen  by double  immunodiffusion  in  agarose 
with goat anti-C5 Ig and  10% NHS as a carrier antigen. After washing to remove free 
radiolabeled  proteins,  the  immunoprecipitates  were  analyzed  for  precipitated  14C- 
labeled C5  antigen  by autoradiography with X-ray film. Radiolabeled  C5  antigen 
was detected in five out of five immunoprecipitation tests performed with extracts of 
monocytes at days 4, 7, and 11 of in vitro serum-free culture; however, no radiolabeled 
C5  antigen  was  detected  (0/9  tests)  on  days  1,  2,  or  3.  In  other  experiments,  an 
attempt was made to promote C5 synthesis by monocytes on days  1-3 of culture by 
adding  2-5% autologous serum to the culture media; however, no effect was noted. 
C5  antigen  was  detected  in  extracts of monocytes maintained  in  serum-containing 
cultures  only  after  day  3.  It  is  significant  that  monocytes  incubated  under  these 
conditions  do not  acquire responsiveness to Bb-induced  spreading until  after day 3 
(11). 
Inhibition  of  Bb-induced MonocyUs Spreading  by  Anti-C5  Fab  and  Fab' Antibody 
Fragments.  The  possible  role  of C3  and  C5  in  the  factor  Bb-induced  monocyte 
spreading reaction was investigated by treating monocytes with Fab antibody frag- 
ments directed  toward  these proteins.  Monocytes were treated  at  37°C  for 30  min 
with dilutions of anti-C3 or anti-C5 Fab and Fab'; Bb was then added to the assays 
and the percentage of cells spread was determined 3 h  later. The results presented in 
Fig. 3 indicate that anti-C5 Fab or Fab' inhibited monocyte spreading by up to 95%. 
Less than  10% of monocytes treated  with  anti-C5 Fab' were observed to be spread 
compared wth 60-90% spread in control cultures receiving Bb alone. Anti-C3 Fab or 
Fab' did not  inhibit  monocyte spreading induced by Bb  (Fig.  3). We reasoned that 
anti-C5 Fab' might exert its inhibitory effect on monocyte spreading by binding to 
cell surface C5 antigen. To test whether such binding of anti-C5 Fab' was a sufficient 
condition  for the expression  of its inhibitory activity, monocytes were treated  with 
anti-C5 Fab', washed, and then Bb was added. As a  control, monocytes were treated 
in a similar manner with anti-C3 Fab'. The results presented in Table I indicate that 
a  brief exposure to anti-C5 Fab' was sufficient to inhibit  a  significant percentage of 
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F[o.  3.  Inhibition by goat anti-C5 Fab and  Fab' antibody fragments of the spreading reaction 
induced by factor Bb (Fab and Fab' protein concentration 10-12 mg/ml before dilution). A, anti- 
C3 Fab' or Fab; D, anti-C5 Fab; O, anti-C5 Fab'. 
TABLE  I 
Inhibition of Bb-induced Monocyte Spreading by Pretreatment of Monocytes 
with Anti-C5 Fab' Antibody Fragments  * 
Inhibi-  Condi-  tion of 
Designation  Treatment  tions  Addition  Spreading§  spread- 
wash:~  ing  H 
%  % 
Negative control  None  -  None  7 zlz 7  - 
Positive control  None  -  Bb  43 -  9  0 
Experimental  Anti-C3 Fab'  -  Bb  41 +  4  6 
Experimental  Anti-C3 Fab'  +  Bb  59 +  9  0 
Experimental  Anti-C5 Fab'  -  Bb  16 ±  3  75 
Experimental  Anti-C5 Fab'  +  Bb  24 ±  7  53 
* Assay with 3-d human monocyte cultures. 
:1: Monocytes were incubated for 20 min at 22°C with a  1:4 dilution of Fab', 
washed  (as indicated)  with medium three times,  and  then tested  for their 
ability to become spread when Bb (3 p,g/ml) was added. 
§ Percentage of cells ±  SD after 3 h at 37°C. 
I] Inhibition of spreading =  1.0 - 
(spreading  experimental) -  (spreading  negative control)  ×  100. 
(spreading  positive control)  -  (spreading  negative control) 
by Bb was inhibited by 53% when monocytes were pretreated  for 20 rain at  20°C.  In 
contrast,  pretreatment  with anti-C3 Fab' was without effect (Table I).  (Anti-C5 Fab' 
did not  cause cells that  were already spread  to become unspread).  Experiments  were 
next  conducted  to  quantitatively  compare  the  inhibitory  activity of anti-C5  Fab'  in 
monocyte  spreading  assays  with  the  inhibitory  activity  in  complement  hemolytic 
assays.  (Anti-C5  Fab'  used  in  these  experiments  was  the  same  as  that  used  in  the 
experiments  presented  in  Fig.  3  and  Table  I.)  It  was  found  that  anti-C5  Fab'  (a) 
inhibited  by 50% the monocyte spreading  reaction of 1-2  X  105 cells at  a  dilution of JOHN  S.  SUNDSMO  AND  OTTO  G()TZE  769 
1:30  (corresponding to 30-90 #g/ml Fab'); and (b) inhibited  1.5 Z of C5 (0.2-0.5 #g) 
hemolytic activity at a  1:300 dilution. 
The specificity  of the anti-C5  Fab'  inhibitory  effect on  monocyte  spreading  was 
investigated by absorbing anti-C5 Fab' with highly purified C5. For these studies, C5 
was purified by conventional  techniques  (12),  and then subjected  to further purifi- 
cation by electrophoresis on the elution from alkaline polyacrylamide gels (23). Anti- 
C5  Fab  was titered  to determine  the  lowest  dilution  giving  95-100%  inhibition  of 
monocyte spreading, this dilution was then absorbed with 1-10 #g of highly purified 
C5 for 15 rain at 22°C. The results presented in Table II indicate that  1-10/~g of C5 
absorbed  70-100%  of the  inhibitory  activity  of a  1:24  dilution  of anti-C5  Fab'. 
Monocytes in control cultures treated with <10 #g C5 per assay and no anti-C5 Fab' 
spread in a normal manner (Table II). 
We reasoned that if factor Bb exerts its effects on monocytes by interacting with C5 
on  the  cell-surface,  the  addition  of relatively  large  amounts  of C5  to  the  reaction 
TABLE  II 
Inhibition of Bb-induced Monocyte Spreading by Anti-C5 Fab ': Addition of C5 
Antigen Reverses the Inhibitory Effect * 
Experi-  Addition:~  Fab'§  C5  Spreading  Inhibi- 
ment  tion]l 
I~g/assay  Ixg/assay  %  % 
1  None  0  0  16 ±  1  -- 
Bb  0  0  65 ±  9  0 
Bb  0  10  66 +  5  0 
Bb  280  0  6 ±  4  100 
Bb  280  l  38 ±  4  55 
Bb  280  2.5  44 +  4  43 
Bb  280  5  59 ±  7  12 
Bb  280  10  59 ±  12  12 
2  None  0  0  10 ±  1  -- 
Bb  0  0  53 ±  10  0 
Bb  0  10  52 ±  5  0 
Bb  170  0  9 ±  1  100 
Bb  170  1  17 ±  3  84 
Bb  170  2.5  7 ±  0  100 
Bb  170  5  58 ±  13  0 
Bb  170  10  44 ±  7  21 
3  None  0  0  10 ±  4  -- 
Bb  0  0  43 ±  4  0 
Bb  0  0  44 ±  3  0 
Bb  250  0  11 ±  1  97 
Bb  250  2.5  33 ±  13  30 
Bb  250  5  32 ±  18  33 
Bb  250  7.5  41  ±  7  6 
* Assay with 3-d human monocyte cultures. 
:[: 3 "/~g Bb/ml. 
§ The minimum amount of anti-C5 Fab' needed to give 90-100% inhibition of 
Bb-dependent spreading. 
U  Percent inhibition =  (spreading Bb +  Fab') -  (spreading none)  ×  100. 
(spreading Bb) -  (spreading none) 770  COMPLEMENT-DEPENDENT  MONOCYTE  SPREADING 
mixture might competitively inhibit the action of Bb. The results presented in Table 
III confirm this hypothesis and indicate that 25-50 #g of C5 inhibit the monocyte 
spreading reaction induced by 1 #g of factor Bb. In data not presented here, control 
experiments were performed in which up to 200/~g of human IgG (Cohn fraction II), 
human albumin, or ovalbumin were  added to the monocyte spreading assay. The 
addition of these proteins to the assay did not inhibit monocyte spreading induced by 
factor Bb. The addition of C5 to monocytes that had already been induced by Bb to 
become spread did not cause these cells to become unspread. 
Discussion 
The spreading of mononuclear phagocytes has been viewed as one in vitro mani- 
festation of a  state of increased macrophage activity in vivo. Recently, it has been 
shown that  the central serine  esterase  of the  alternative pathway of complement 
activation, Bb,  induces murine macrophages  (10) and  human monocytes (11) to 
become spread on a  glass substrata. It has also been established that to induce the 
spreading reaction, the catalytic site of the Bb enzyme must be structurally intact 
since treatment of Bb with heat (56°C  for 30 min.) or diisopropyl fluorophosphate 
(10  -~ M) destroyed both enzymatic and spreading activities (9-12). 
Native factor B is a single chain polypeptide of 93,000 mol wt, which enters into an 
Mg÷+-dependent complex with G3b  (C3b,B) and is cleaved by factor D, yielding 
fragments of 60,000 and 33,000 mol wt (14), termed Bb and Ba, respectively (9,  12 
14). Binding and cleavage of B initiate formation of the C3b,Bb complex,  which is 
the G3/G5 convertase of the APC.  The serine  esterase  activity of this complex is 
associated  with Bb (9,  12-15), whereas the localization of the complex on biological 
membranes is a property of the C3b molecule, which transiently expresses an active 
thioester group that can form covalent bonds with molecules in the surface of  particles 
that activate the APC (26-32).  Cleavage of C3 by cell-bound G3b,Bb  leads  to the 
deposition of additional G3b molecules on the surface that are required to express C5 
convertase activity (33). It has recently become apparent that cell-bound C3b or fluid- 
phase C3b  (34) binds to C5 with a  low affinity; and that such cell-bound (33) or 
fluid-phase-complexed (34) G5 is susceptible  to cleavage by the APC C5 convertase. 
TABLE  III 
Inhibition by C5 of Bb-induced Mono~te Spreading 
Addition*  C5  Spreading  Inhibition:~ 
#g/assay  % 
None  0  10 :t: 4  -- 
Bb  0  43 +  4  0 
Bb  50  12 :t: 5  94 
Bb  35  9 :t: 3  100 
Bb  25  9 ±  5  [00 
Bb  20  52 ±  7  0 
Bb  10  59 +  12  0 
Assay with 3-d monocyte cultures;  1-3 ×  10  s monocytes per assay. 
* 3/~g Bb/ml. 
(spreading Bb +  05) -  (spreading none) 
:~ Percent inhibition I  X  100. 
(spreading Bb) -  (spreading none) JOHN S. SUNDSMO AND OTTO GOTZE  771 
In molecular terms, it is probable that expression of C5 convertase activity involves 
binding of C5  to multiple C3b molecules where one or more of the C3b molecules 
also contains  bound  Bb  enzyme.  Bb  released  from the C3b,Bb complex by decay 
dissociation fails to bind to C3b, causing it to lose its potential as a significant C3 or 
C5 convertase (9). However, free Bb retains esterolytic activity on synthetic substrates 
(9,  12-15) and a limited ability to cleave plasminogen (35) and prothrombin (36). It 
is possible that under appropriate conditions, free Bb may also cleave C3 and C5 or 
that  Bb may to a  limited extent be able to reform a  C3b,Bb complex on the cell 
surface. 
The restricted substrate specificity of factor Bb in the complement system raised a 
question  about  whether  either  of the  natural  substrates  of Bb  might  serve  as  a 
monocyte surface substrate for Bb in inducing the monocyte spreading reaction. In 
preparation for the present study, experiments were conducted to define the optimum 
conditions for stimulation  of monocyte spreading  by factor Bb, and  the  results of 
these  experiments  have  been  published  previously  (11).  Studies  have  also  been 
initiated to investigate whether Bb stimulates changes in monocyte "marker-enzyme" 
systems and it has been found that Bb stimulates (a) a chemilluminescence response 
in 3-d serum-free cultures of human peripheral blood monocytes and (b) plasminogen 
activator secretion (J. S. Sundsmo, unpublished data). Significantly, it was found that 
human  peripheral  blood  monocytes  require  3  d  incubation  in  vitro  to  acquire 
responsiveness to factor Bb-induced spreading (11). This finding caused us to inves- 
tigate in the present study whether the surface expression of C3 or C5 on monocytes 
changed  during in  vitro culture in  serum-free medium  and  it was  found that  the 
percentage of monocytes staining positively for C3 or C5 was 6 +  7% at the initiation 
of in vitro culture, and that anti-C5 staining increased to 70 +  6% after 3 d incubation 
in serum-free medium, whereas C3 staining remained constant (Fig.  1). Biosynthesis 
of C5 by monocytes was investigated using [x4C]- and [3H]leueine, immunoprecipita- 
tion techniques, and SDS-PAGE to evaluate C5 antigens in Triton X-100 extracts of 
monocytes.  It  was  found  that  monocytes incorporate  radiolabeled  leucine  into  a 
protein with an apparent mol wt of 180,000, which is antigenically similar to serum 
C5  (Fig. 2); and that the radiolabeled C5 antigen was only detected in cell extracts 
after 3 d of in vitro incubation. It is perhaps significant that C5 may be acquired by 
human  monocytes during a  time in which monocyte maturation into macrophages 
has been recognized to take place in vitro (37-39). The finding of biosynthetically 
radiolabeled C5  confirms and  extends the  observations of Stecher and  Thorbecke 
(40), Levy et al.  (41), and Ooi and Colten  (42, 43), and Ooi et al.  (44), who have 
reported that murine macrophages synthesize C5. 
Involvement of cell-surface C3 or C5 in the monocyte spreading reaction induced 
by factor Bb was investigated in the present study by testing for the ability of anti-C3 
and anti-C5 Fab' fragments to inhibit the spreading reaction induced by factor Bb. 
Anti-C5 Fab' (but not anti-C3 Fab') was found to block by up to 100% the spreading 
induced by factor Bb in a serum-free system (Fig.  3). Inhibition by anti-C5 Fab' was 
found to be exerted in a dose-dependent fashion (Fig. 3) and the inhibitory effect was 
exerted  when  monocytes were  treated  with  anti-C5  Fab'  and  washed  before  the 
addition of factor Bb (Table I), suggesting that anti-C5 Fab' exerts its inhibitory effect 
on the monocyte spreading reaction by binding to monocytes rather than by interfer- 
ing with some presumptive fluid-phase reaction involving factor Bb. The antigenic 772  COMPLEMENT-DEPENDENT MONOCYTE  SPREADING 
specificity of this inhibitory effect was established by absorbing anti-C5 Fab' with 
PAGE-purified C5 and this treatment caused the inhibitory activity of anti-C5 Fab' 
to be  quantitatively decreased.  We reasoned that  if factor Bb exerts  its  effect  on 
monocytes by interacting with cell-surface C5, then the addition of purified C5 to the 
reaction mixture might competitively inhibit the action of Bb on monocyte surface 
C5. This hypothesis was confirmed when it was found that fluid-phase C5 inhibited 
the action of Bb if it was added in 20-100-fold  molar excess of the amount of factor 
Bb  needed  to  induce  the  monocyte spreading reaction  (Table  III).  These  results 
suggest a previously unrecognized property of Bb, namely, that purified Bb interacts 
with C5 on the monocyte surface or in fluid phase in the absence of C3b. 
The results presented here are analogous to those we have reported previously (45) 
in a study designed to investigate expression of complement proteins on lymphocytes 
and the possible functional role of C5 in lymphocyte activation. In that study, human 
peripheral blood lymphocytes were found to synthesize C5, which had an apparent 
mol wt of 180,000 on SDS-PAGE; lymphocytes stimulated with phytohemagglutinin 
incorporated [x4C]leueine into C5, C6, C7, and C8 antigens as detected by immuno- 
precipitation  in  two-directional  immunodiffusion and  autoradiography (45); and 
anti-C5 Fab' antibody fragments inhibited lymphocyte stimulation by phytohemag- 
glutinin-mitogen or allogeneic mixed lymphocyte culture as determined by inhibition 
of [SH]thymidine incorporation (46). 
It is established that many agents induce monocyte spreading in vitro (7). What is 
unique about factor Bb of the complement system is that mononuclear phagocytes 
have been reported to synthesize factor B (47-49),  factor D (48, 50), C3 (40, 51-53) 
and C3b inactivator (50, 54), giving these cells the potential to activate complement 
through the alternative pathway and to regulate complement activation. In addition, 
elastase, which is associated with mononuclear phagocytes (55, 56), has been shown 
to  cleave  C3  generating  a  "C3b-like"  fragment, which  is  functionally active  in 
consuming factor B (56); and, plasmin, which is also capable of cleaving factor B (14) 
and C3 (57), has been shown to be formed following  secretion ofplasminogen activator 
from "activated" macrophages (58-60). Leukocytes and lymphoblastoid cells activate 
complement (25, 61-70); cellular receptors have been identified that bind complement 
activation fragments  (71), and  the  Bb  complement activation fragment has been 
implicated as a potential mediator of macrophage migration inhibition (72), and C5a 
also exerts profound effects on neutrophils (73). 
Complement has  been  considered a  mediator of humoral  immunity, active  in 
antibody-mediated lysis  of bacteria  and  cells,  and  in  anaphylactic  and  Arthus 
reactions.  The recognition that lymphocytes and monocytes synthesize and activate 
complement, and  that  factor Bb  induces significant changes in  the physiology of 
mononuclear phagocytes, raises the possibility that proteins of the leukocyte comple- 
ment system may also serve as mediators of cellular immunity. 
Summary 
The  central  serine  esterase  of the  alternative  pathway of complement  (APC) 
activation,  activated  factor  B  (Bb),  has  been  shown  recently  to  induce  murine 
macrophages and human monocytes to become spread on a  glass substrata. It has 
also been established that to induce the spreading reaction, the catalytic site of the Bb 
enzyme must be structurally intact since treatment of Bb with heat (56°C for 30 min) JOHN S.  SUNDSMO AND OTTO GOTZE  773 
or  diisopropylfluorophosphate  (10  -3  M)  destroyed  both  enzymatic  and  spreading 
activities. In the C3b,Bb complex, Bb exhibits restricted substrate specificity for C3 
and C5. With this in mind, the role of C3 and C5 in the monocyte spreading reaction 
was explored in the present study. Expression of C3 and C5 on the surface of human 
peripheral  blood  monocytes  was  investigated  by  the  direct  fluorescent  antibody 
technique  employing  fluorescein  isothiocyanate-conjugated  anti-C3  or  C5  F(ab')2 
antibody fragments. It was found that C3 and C5 were present on 6 +  7% of freshly 
prepared monocytes and  that  expression of C5,  but  not  C3,  increased  to  70  _  6% 
when  monocytes were incubated  for 3  d  in  serum-free medium.  Biosynthesis of C5 
was  indicated  when  it  was  found  that  under  serum-free  conditions,  monocytes 
incorporated  [3H]leucine into  immunoprecipitable C5  with  an  apparent  mol wt  of 
180,000 on sodium dodecyl sulfate-polyacrylamide gel electrophoresis. The role of C3 
and C5  in  the monocyte spreading reaction  induced  by factor Bb was explored by 
testing  for  the  ability  of anti-C3  and  anti-C5  Fab'  antibody  fragments  to  block 
monocyte spreading. It was found that anti-C5 Fab' inhibited by up to 100% the 3-h 
human monocyte spreading reaction induced by Bb; in contrast, anti-C3 Fab' or anti- 
C4 Fab' inhibited by <10%. That the inhibitory effect of anti-C5 Fab' was exerted 
directly on the monocyte was established when it was found that the 3-h monocyte 
spreading reaction was significantly inhibited by pretreating monocytes with anti-C5 
Fab' for 20 min and then washing before the addition  of Bb. The specificity of the 
inhibitory  effect  of anti-C5  Fab'  was  established  by  quantitatively  absorbing  the 
antibody  fragments  with  polyacrylamide  gel-purified  C5  antigen:  >4  /~g  of  C5 
absorbed by 100% the inhibitory activity of 10-20/~g of anti-C5 Fab'. That factor Bb 
exerted  its  effect  on  monocytes  by  interacting  directly  with  cell  surface  C5  was 
indicated  when  it  was  found  that  purified  C5  inhibited  the  monocyte  spreading 
reaction  induced  by Bb;  :>25  #g of C5  inhibited  by  100%  the  spreading  reaction 
induced by 3 #g factor Bb. 
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